MicroRNA-29b mediates altered innate immune development in acute leukemia

Journal of Clinical Investigation

Volumn 126, Issue 12, 2016, Pages 4404-4416

  Mundy Bosse, Bethany L ^a   Scoville, Steven D ^b   Chen, Li ^a   McConnell, Kathleen ^a   Mao, Hsiaoyin C ^a   Ahmed, Elshafa H ^a   Zorko, Nicholas ^c   Harvey, Sophia ^d   Cole, Jordan ^e   Zhang, Xiaoli ^f   Costinean, Stefan ^g   Croce, Carlo M ^h,i   Larkin, Karilyn ^a   Byrd, John C ^a,i   Vasu, Sumithira ^a,i   Blum, William ^a,i   Yu, Jianhua ^a,i   Freud, Aharon G ^a,i   Caligiuri, Michael A ^a,h  

^a Oncology and Bone Marrow Transplantation   (United States)

^b Medical Scientist Training Program   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

^d MICHIGAN STATE UNIVERSITY   (United States)

^e THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^f Center for Biostatistics   (United States)

^g Department of Pathology and Microbiology ^*  (United States)

^h UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

ⁱ OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GRANZYME B; MICRORNA 29B; PERFORIN; EOMES PROTEIN, HUMAN; EOMES PROTEIN, MOUSE; GRANZYME; GZMB PROTEIN, MOUSE; MICRORNA; MIRN29 MICRORNA, HUMAN; MIRN29 MICRORNA, MOUSE; RNA; T BOX TRANSCRIPTION FACTOR; T-BOX TRANSCRIPTION FACTOR TBX21; TUMOR PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL DEATH; CELL DIFFERENTIATION; CELL MATURATION; CELL PROLIFERATION; CONTROLLED STUDY; DE NOVO ACUTE MYELOID LEUKEMIA; GENE DELETION; HOMEOSTASIS; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INNATE IMMUNITY; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; ACUTE MYELOID LEUKEMIA; ANIMAL; GENETICS; IMMUNOLOGY; PATHOLOGY; TRANSGENIC MOUSE; TUMOR CELL LINE; TUMOR ESCAPE;

ANIMALS; CELL LINE, TUMOR; GRANZYMES; HUMANS; IMMUNITY, INNATE; KILLER CELLS, NATURAL; LEUKEMIA, MYELOID, ACUTE; MICE; MICE, TRANSGENIC; MICRORNAS; NEOPLASM PROTEINS; PERFORIN; RNA, NEOPLASM; T-BOX DOMAIN PROTEINS; TUMOR ESCAPE;

EID: 85002851532     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI85413     Document Type: Article

References (62)

1. SEER Cancer Statistics Review, 1975-2012. National Cancer Institute. http://seer.cancer.gov/csr/1975-2012. Published April 2015. Accessed September 20, 2016.
2. Yu J, Freud AG, Caligiuri M.A. Location and cellular stages of natural killer cell development. Trends Immunol. 2013;34(12):573-582.
3. Miller JS, et al. Successful adoptive transfer and in vivo expansion of human haploiden-tical NK cells in patients with cancer. Blood. 2005;105(8):3051-3057.
4. Ruggeri L, et al. Effectiveness of donor natural killer cell alloreactivity in mis-matched hematopoietic transplants. Science. 2002;295(5562):2097-2100.
5. Tratkiewicz JA, Szer J. Loss of natural killer activity as an indicator of relapse in acute leukaemia. Clin Exp Immunol. 1990;80(2):241-246.
6. Pross HF, Lotzová E. Role of natural killer cells in cancer. Nat Immun. 1993;12(4-5):279-292.
7. Tajima F, Kawatani T, Endo A, Kawasaki H. Natural killer cell activity and cytokine production as prognostic factors in adult acute leukemia. Leukemia. 1996;10(3):478-482.
8. Lion E, Willemen Y, Berneman ZN, Van Ten-deloo VF, Smits EL. Natural killer cell immune escape in acute myeloid leukemia. Leukemia. 2012;26(9):2019-2026.
9. Salih HR, et al. Functional expression and release of ligands for the activating immu-noreceptor NKG2D in leukemia. Blood. 2003;102(4):1389-1396.
10. Diermayr S, et al. NKG2D ligand expression in AML increases in response to HDAC inhibitor valproic acid and contributes to allorecognition by NK-cell lines with single KIR-HLA class I specificities. Blood. 2008;111(3):1428-1436.
11. Cooley S, et al. Donor selection for natural killer cell receptor genes leads to superior survival after unrelated transplantation for acute myelogenous leukemia. Blood. 2010;116(14):2411-2419.
12. Zhang L, Gajewski TF, Kline J. PD-1/PD-L1 interactions inhibit antitumor immune responses in a murine acute myeloid leukemia model. Blood. 2009;114(8):1545-1552.
13. Ahmad SM, Svane IM, Andersen MH. The stimulation of PD-L1-specific cytotoxic T lymphocytes can both directly and indirectly enhance antileu-kemic immunity. Blood Cancer J. 2014;4:e230.
14. Zhong RK, Loken M, Lane TA, Ball ED. CTLA-4 blockade by a human MAb enhances the capacity of AML-derived DC to induce T-cell responses against AML cells in an autologous culture sys-tem. Cytotherapy. 2006;8(1):3-12.
15. Nguyen S, et al. HLA-E upregulation on IFN-gamma-activated AML blasts impairs CD94/NKG2A-dependent NK cytolysis after haplo-mismatched hematopoietic SCT. Bone Marrow Transplant. 2009;43(9):693-699.
16. Benson DM, et al. A phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma. Blood. 2012;120(22):4324-4333.
17. Hayakawa Y, Smyth MJ. CD27 dissects mature NK cells into two subsets with distinct responsiveness and migratory capacity. J Immunol. 2006;176(3):1517-1524.
18. Chiossone L, Chaix J, Fuseri N, Roth C, Vivier E, Walzer T. Maturation of mouse NK cells is a 4-stage developmental program. Blood. 2009;113(22):5488-5496.
19. Caligiuri M.A. Human natural killer cells. Blood. 2008;112(3):461-469.
20. Freud AG, Yu J, Caligiuri M.A. Human natural killer cell development in secondary lymphoid tissues. Semin Immunol. 2014;26(2):132-137.
21. Townsend MJ, et al. T-bet regulates the terminal maturation and homeostasis of NK and Valpha14i NKT cells. Immunity. 2004;20(4):477-494.
22. Gordon SM, et al. The transcription factors T-bet and Eomes control key checkpoints of natural killer cell maturation. Immunity. 2012;36(1):55-67.
23. Steiner DF, et al. MicroRNA-29 regulates T-box transcription factors and interfer-on-? production in helper T cells. Immunity. 2011;35(2):169-181.
24. Sullivan RP, et al. MicroRNA-15/16 antagonizes Myb to control NK cell maturation. J Immunol. 2015;195(6):2806-2817.
25. Ma F, et al. The microRNA miR-29 controls innate and adaptive immune responses to intra-cellular bacterial infection by targeting interfer-on-?. Nat Immunol. 2011;12(9):861-869.
26. Leong JW, Sullivan RP, Fehniger TA. micro-RNA management of NK-cell developmental and functional programs. Eur J Immunol. 2014;44(10):2862-2868.
27. Smith KM, et al. miR-29ab1 deficiency identifies a negative feedback loop controlling Th1 bias that is dysregulated in multiple sclerosis. J Immunol. 2012;189(4):1567-1576.
28. Bernot KM, et al. Eradicating acute myeloid leukemia in a Mll(PTD/wt):Flt3(ITD/wt) murine model: a path to novel therapeutic approaches for human disease. Blood. 2013;122(23):3778-3783.
29. Costello RT, et al. Defective expression and function of natural killer cell-triggering receptors in patients with acute myeloid leukemia. Blood. 2002;99(10):3661-3667.
30. Dulphy N, et al. An unusual CD56(bright) CD16(low) NK cell subset dominates the early posttransplant period following HLA-matched hematopoietic stem cell transplantation. J Immunol. 2008;181(3):2227-2237.
31. Siegler U, Kalberer CP, Nowbakht P, Sendelov S, Meyer-Monard S, Wodnar-Filipowicz A. Activated natural killer cells from patients with acute myeloid leukemia are cytotoxic against autologous leukemic blasts in NOD/SCID mice. Leukemia. 2005;19(12):2215-2222.
32. Kim S, et al. In vivo developmental stages in murine natural killer cell maturation. Nat Immunol. 2002;3(6):523-528.
33. Huntington ND, et al. NK cell maturation and peripheral homeostasis is associated with KLRG1 up-regulation. J Immunol. 2007;178(8):4764-4770.
34. Stringaris K, et al. Leukemia-induced pheno-typic and functional defects in natural killer cells predict failure to achieve remission in acute myeloid leukemia. Haematologica. 2014;99(5):836-847.
35. Fauriat C, et al. Deficient expression of NCR in NK cells from acute myeloid leukemia: Evolution during leukemia treatment and impact of leukemia cells in NCRdull phenotype induction. Blood. 2007;109(1):323-330.
36. Baessler T, et al. Glucocorticoid-induced tumor necrosis factor receptor-related protein ligand subverts immunosurveillance of acute myeloid leukemia in humans. Cancer Res. 2009;69(3):1037-1045.
37. Otten HG, van Ginkel WG, Hagenbeek A, Petersen EJ. Prevalence and clinical significance of resistance to perforin-and FAS-mediated cell death in leukemia. Leukemia. 2004;18(8):1401-1405.
38. Lehmann C, Zeis M, Schmitz N, Uharek L. Impaired binding of perforin on the surface of tumor cells is a cause of target cell resistance against cytotoxic effector cells. Blood. 2000;96(2):594-600.
39. Khaznadar Z, et al. Defective NK cells in acute myeloid leukemia patients at diagnosis are associated with blast transcriptional signatures of immune evasion. J Immunol. 2015;195(6):2580-2590.
40. Cooper MA, et al. Human natural killer cells: a unique innate immunoregulatory role for the CD56(bright) subset. Blood. 2001;97(10):3146-3151.
41. Dauguet N, Récher C, Demur C, Fournié JJ, Poupot M, Poupot R. Pre-eminence and per-sistence of immature natural killer cells in acute myeloid leukemia patients in first complete remission. Am J Hematol. 2011;86(2):209-213.
42. Freud AG, Caligiuri M.A. Human natural killer cell development. Immunol Rev. 2006;214:56-72.
43. Garzon R, et al. MicroRNA 29b func-tions in acute myeloid leukemia. Blood. 2009;114(26):5331-5341.
44. Garzon R, et al. MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia. Blood. 2008;111(6):3183-3189.
45. Liu S, et al. Sp1/NF?B/HDAC/miR-29b regulatory network in KIT-driven myeloid leukemia. Cancer Cell. 2010;17(4):333-347.
46. Huan J, et al. RNA trafficking by acute myelog-enous leukemia exosomes. Cancer Res. 2013;73(2):918-929.
47. Yeh YY, et al. Characterization of CLL exosomes reveals a distinct microRNA signature and enhanced secretion by activation of BCR signaling. Blood. 2015;125(21):3297-3305.
48. Szajnik M, Czystowska M, Szczepanski MJ, Mandapathil M, Whiteside TL. Tumor-derived microvesicles induce, expand and up-regulate biological activities of human regulatory T cells (Treg). PLoS One. 2010;5(7):e11469.
49. Szczepanski MJ, Szajnik M, Welsh A, Whiteside TL, Boyiadzis M. Blast-derived microvesicles in sera from patients with acute myeloid leukemia suppress natural killer cell function via mem-brane-associated transforming growth factor-ß1. Haematologica. 2011;96(9):1302-1309.
50. Whiteside TL. Immune modulation of T-cell and NK (natural killer) cell activities by TEXs (tumour-derived exosomes). Biochem Soc Trans. 2013;41(1):245-251.
51. Clayton A, Mitchell JP, Court J, Linnane S, Mason MD, Tabi Z. Human tumor-derived exosomes down-modulate NKG2D expression. J Immunol. 2008;180(11):7249-7258.
52. Wu C, et al. Clonal tracking of rhesus macaque hematopoiesis highlights a distinct lineage origin for natural killer cells. Cell Stem Cell. 2014;14(4):486-499.
53. Huntington ND, et al. IL-15 trans-presentation promotes human NK cell development and differentiation in vivo. J Exp Med. 2009;206(1):25-34.
54. Lopez-Vergès S, et al. CD57 defines a functionally distinct population of mature NK cells in the human CD56dimCD16+ NK-cell subset. Blood. 2010;116(19):3865-3874.
55. Romagnani C, et al. CD56brightCD16-kill-er Ig-like receptor-NK cells display longer telomeres and acquire features of CD56dim NK cells upon activation. J Immunol. 2007;178(8):4947-4955.
56. Yu J, et al. CD94 surface density identifies a functional intermediary between the CD56bright and CD56dim human NK-cell subsets. Blood. 2010;115(2):274-281.
57. Fehniger TA, et al. CD56bright natural killer cells are present in human lymph nodes and are activated by T cell-derived IL-2: a potential new link between adaptive and innate immunity. Blood. 2003;101(8):3052-3057.
58. Zorko NA, et al. Mll partial tandem duplication and Flt3 internal tandem duplication in a double knock-in mouse recapitulates features of counterpart human acute myeloid leukemias. Blood. 2012;120(5):1130-1136.
59. Cushing L, et al. Disruption of miR-29 leads to aberrant differentiation of smooth muscle cells selectively associated with distal lung vascula-ture. PLoS Genet. 2015;11(5):e1005238.
60. Trotta R, et al. Overexpression of miR-155 causes expansion, arrest in terminal differentiation and functional activation of mouse natural killer cells. Blood. 2013;121(16):3126-3134.
61. Trotta R, et al. miR-155 regulates IFN-? production in natural killer cells. Blood. 2012;119(15):3478-3485.
62. Deng Y, et al. Transcription factor Foxo1 is a negative regulator of natural killer cell maturation and function. Immunity. 2015;42(3):457-470.